XL-protein GmbH

XL-protein GmbH is a leading biotechnology research company specializing in the development and commercialization of its proprietary PASylation® technology. This innovative technology is designed to extend the in vivo half-life of biopharmaceuticals, enhancing their therapeutic potential. XL-protein's PASylation® technology offers a unique approach to improving the efficacy and duration of biopharmaceutical treatments.

Located at Lise-Meitner-Strasse 30, Freising, D-85354, DE, XL-protein is dedicated to advancing biopharmaceutical solutions through cutting-edge research and development. The company focuses on creating innovative methods to optimize the performance of therapeutic proteins and peptides, ensuring they remain effective for longer periods within the body. XL-protein’s approach involves genetically fusing or chemically conjugating conformationally disordered amino acid sequences to therapeutic agents, creating a solvated biopolymer that increases the size and, therefore, the half-life of the biopharmaceutical.

XL-protein GmbH is committed to pioneering advancements in the biotechnology field, offering solutions that improve patient outcomes and redefine biopharmaceutical standards. We invite the management team at XL-protein to enrich your company’s profile by creating a customized and exclusive company showcase and product listing on our platform, further highlighting your groundbreaking PASylation® technology.